How would you approach patients with ALK-positive metastatic NSCLC who progress on crizotinib and subsequently alectinib?
In the absence of clinical trial, is there are role for dose-escalating alectinib, or would you consider brigatinib or chemotherapy?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Wexner Medical Center at The Ohio State University
Answered on
Ideally, I would biopsy the recurrence to determine if there is a defined resistance mutation that might be targetable by brigatinib or lorlatinib. I always try to maintain TKIs as long as possible. Dose escalation might be effective, but would not be my first choice. If none of these are options, r...
Join for free or sign in to see the full answer